Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DFTX NASDAQ:GRAL NASDAQ:PSNL NASDAQ:WGS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDFTXDefinium Therapeutics$23.29-0.6%$19.86$6.03▼$26.25$2.32B2.371.84 million shs1.12 million shsGRALGRAIL$62.29-0.7%$50.79$29.95▼$118.84$2.67B3.031.12 million shs436,170 shsPSNLPersonalis$5.96-1.9%$6.97$3.84▼$11.50$624.42M1.961.59 million shs1.11 million shsWGSGeneDx$40.70+17.2%$69.45$32.21▼$170.87$1.19B2.06946,281 shs3.38 million shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDFTXDefinium Therapeutics+4.55%+14.30%+14.64%+44.12%+270.86%GRALGRAIL+15.39%+26.33%+21.33%-33.26%+95.19%PSNLPersonalis+9.17%+20.44%-7.75%-18.08%+51.75%WGSGeneDx+0.58%-44.82%-47.89%-58.72%-45.14%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDFTXDefinium Therapeutics$23.29-0.6%$19.86$6.03▼$26.25$2.32B2.371.84 million shs1.12 million shsGRALGRAIL$62.29-0.7%$50.79$29.95▼$118.84$2.67B3.031.12 million shs436,170 shsPSNLPersonalis$5.96-1.9%$6.97$3.84▼$11.50$624.42M1.961.59 million shs1.11 million shsWGSGeneDx$40.70+17.2%$69.45$32.21▼$170.87$1.19B2.06946,281 shs3.38 million shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDFTXDefinium Therapeutics+4.55%+14.30%+14.64%+44.12%+270.86%GRALGRAIL+15.39%+26.33%+21.33%-33.26%+95.19%PSNLPersonalis+9.17%+20.44%-7.75%-18.08%+51.75%WGSGeneDx+0.58%-44.82%-47.89%-58.72%-45.14%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDFTXDefinium Therapeutics 3.07Buy$38.0063.16% UpsideGRALGRAIL 2.38Hold$67.888.97% UpsidePSNLPersonalis 2.57Moderate Buy$11.5093.12% UpsideWGSGeneDx 2.67Moderate Buy$96.43136.94% UpsideCurrent Analyst Ratings BreakdownLatest PSNL, GRAL, DFTX, and WGS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/6/2026GRALGRAIL TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$65.00 ➝ $69.005/6/2026GRALGRAIL Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$54.00 ➝ $56.005/6/2026GRALGRAIL Robert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$70.005/5/2026WGSGeneDx Craig HallumSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$85.005/5/2026WGSGeneDx Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetBuy$100.00 ➝ $75.005/5/2026WGSGeneDx Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$155.00 ➝ $75.005/5/2026WGSGeneDx GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$100.00 ➝ $70.005/5/2026WGSGeneDx BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$170.00 ➝ $90.004/24/2026WGSGeneDx Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold4/23/2026DFTXDefinium Therapeutics OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$40.004/22/2026DFTXDefinium Therapeutics Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$23.00 ➝ $30.00(Data available from 5/7/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDFTXDefinium TherapeuticsN/AN/AN/AN/A$3.36 per shareN/AGRALGRAIL$147.17M18.16N/AN/A$66.13 per share0.94PSNLPersonalis$69.65M8.95N/AN/A$2.94 per share2.03WGSGeneDx$442.68M2.69$2.70 per share15.06$8.68 per share4.69Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDFTXDefinium Therapeutics-$183.79M-$2.13N/AN/AN/AN/A-82.07%-58.73%5/7/2026 (Estimated)GRALGRAIL-$408.35M-$11.18N/AN/AN/A-253.22%-16.63%-14.42%N/APSNLPersonalis-$81.27M-$0.91N/AN/AN/A-116.69%-39.13%-29.31%5/7/2026 (Confirmed)WGSGeneDx-$21.02M-$2.68N/A23.94N/A-17.58%9.15%5.21%N/ALatest PSNL, GRAL, DFTX, and WGS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026DFTXDefinium Therapeutics-$0.4780N/AN/AN/AN/AN/A5/7/2026Q1 2026PSNLPersonalis-$0.23N/AN/AN/A$14.49 millionN/A5/5/2026Q1 2026GRALGRAIL-$2.7629-$2.29+$0.4729-$2.29$39.16 million$40.79 million5/4/2026Q1 2026WGSGeneDx-$0.06-$0.28-$0.22-$2.16$112.46 million$102.25 million2/26/2026Q4 2025PSNLPersonalis-$0.31-$0.26+$0.05-$0.26$17.12 million$17.35 million2/23/2026Q4 2025WGSGeneDx$0.11$0.14+$0.03-$0.61$120.80 million$120.99 million2/19/2026Q4 2025GRALGRAIL-$3.33-$2.44+$0.89-$2.44$43.33 million$43.60 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthDFTXDefinium TherapeuticsN/AN/AN/AN/AN/AGRALGRAILN/AN/AN/AN/AN/APSNLPersonalisN/AN/AN/AN/AN/AWGSGeneDxN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDFTXDefinium Therapeutics0.126.296.29GRALGRAILN/A11.9711.97PSNLPersonalisN/A6.766.61WGSGeneDx0.383.092.34Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDFTXDefinium Therapeutics27.91%GRALGRAILN/APSNLPersonalis61.91%WGSGeneDx61.72%Insider OwnershipCompanyInsider OwnershipDFTXDefinium Therapeutics2.26%GRALGRAIL1.85%PSNLPersonalis4.20%WGSGeneDx29.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDFTXDefinium Therapeutics4099.70 million97.45 millionOptionableGRALGRAIL1,36042.92 million42.12 millionOptionablePSNLPersonalis400104.68 million100.28 millionOptionableWGSGeneDx1,30029.29 million20.62 millionOptionablePSNL, GRAL, DFTX, and WGS HeadlinesRecent News About These CompaniesGeneDx Holdings Corp. (WGS) Under Investigation for Potential Securities Law Violations - Contact Levi & Korsinsky Today2 hours ago | newsfilecorp.comNBarrack, Rodos & Bacine Investigates GeneDx Holdings Corp. (NASDAQ: WGS) For Possible Securities FraudMay 7 at 9:30 AM | globenewswire.comGENEDX HOLDINGS CORP. INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities FraudMay 6 at 8:00 PM | businesswire.comGeneDx (NASDAQ:WGS) Sees Large Volume Increase - Should You Buy?May 6 at 5:35 PM | marketbeat.comGeneDX Holdings Investigated for Possible Securities Fraud; Investors Should Contact Block & Leviton to Recover LossesMay 6 at 4:00 PM | newsfilecorp.comNINVESTOR ALERT: Investigation of GeneDx Holdings Corp. (WGS) announced by Holzer & Holzer, LLCMay 6 at 3:04 PM | globenewswire.comSecurities Fraud Investigation Into GeneDx Holdings Corp. (WGS) Announced - Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities ...May 6 at 2:34 PM | tmcnet.comGeneDx Holdings Corp. 2026 Q1 - Results - Earnings Call PresentationMay 6 at 3:31 AM | seekingalpha.comWGS: GeneDX Shares Plummet Over 45%; Investors Should Contact Block & Leviton to ...May 5 at 11:00 PM | bakersfield.comBThe 'alarming' results that caused GeneDx stock to plummet 50%May 5 at 11:00 PM | msn.comWGS: GeneDX Shares Plummet Over 45%; Investors Should Contact Block & Leviton to Potentially Recover Money Through The Firm's InvestigationMay 5 at 6:11 PM | globenewswire.comWGS stock slumps after hours as firm predicts lower test volume for yearMay 5 at 5:59 PM | msn.comSecurities Fraud Investigation Into GeneDx Holdings Corp. (WGS) Announced - Shareholders Who Lost Money Urged to Contact The Law Offices of Frank R. CruzMay 5 at 5:59 PM | tmcnet.comDoes GeneDx’s Guidance Cut And Core Shift Reshape The Bull Case For GeneDx Holdings (WGS)?May 5 at 5:59 PM | finance.yahoo.comThe 'alarming' results that caused GeneDx stock to plummet 49%May 5 at 5:59 PM | msn.comSecurities Fraud Investigation Into GeneDx Holdings Corp. (WGS) Announced – Shareholders Who Lost Money Urged to Contact The Law Offices of Frank R. CruzMay 5 at 3:33 PM | businesswire.comShareholder Alert: Ademi LLP Investigates Claims of Securities Fraud against GeneDx Holdings Corp.May 5 at 2:58 PM | prnewswire.comGeneDx (NASDAQ:WGS) Reaches New 52-Week Low Following Weak EarningsMay 5 at 9:53 AM | marketbeat.comThe 'Alarming' Results That Caused GeneDx Stock To Plummet 45%May 5 at 9:35 AM | investors.comGuggenheim Cuts GeneDx (NASDAQ:WGS) Price Target to $70.00May 5 at 9:07 AM | marketbeat.comBTIG Research Cuts GeneDx (NASDAQ:WGS) Price Target to $90.00May 5 at 8:32 AM | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesWith Nike Shares Near a 12-Year Low, Is Now the Time to Be Brave?By Sam Quirke | April 12, 20263 Dividend Aristocrats Whose Yields Can Help Combat InflationBy Chris Markoch | April 9, 2026The War Won't Last Forever: 3 Stocks That Could Lead the RecoveryBy Bridget Bennett | April 8, 20265 Stocks Positioned to Win the AI Data Center BuildoutBy Bridget Bennett | April 20, 2026These 3 Psychedelic Stocks Activated After Trump's Executive OrderBy Nathan Reiff | April 27, 2026PSNL, GRAL, DFTX, and WGS Company DescriptionsDefinium Therapeutics NASDAQ:DFTX$23.29 -0.13 (-0.56%) As of 03:33 PM EasternMind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.GRAIL NASDAQ:GRAL$62.28 -0.47 (-0.74%) As of 03:50 PM Eastern This is a fair market value price provided by Massive. Learn more.GRAIL, Inc. operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. It utilizes machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. The company was founded by Jeffrey T. Huber, William H. Rastetter, Mostafa Ronaghi, and Richard D. Klausner on September 11, 2015 and is headquartered in Menlo Park, CA.Personalis NASDAQ:PSNL$5.96 -0.12 (-1.89%) As of 03:50 PM Eastern This is a fair market value price provided by Massive. Learn more.Personalis, Inc. develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD) and recurrence in cancer; and ImmunoID NeXT, a tissue-based test that combines whole exome (DNA) and whole transcriptome (RNA) sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample. It also provides NeXT Personal Dx, a tumor-informed liquid biopsy test for detection of MRD and recurrence in cancer; and NeXT Dx, a comprehensive tumor profiling test that unlocks the entire exome (DNA) and transcriptome (RNA) with matched tumor-normal analysis. In addition, the company performs whole exome sequencing (WES) of cancer tissue and matched blood samples for diagnostic companies as an input to their products; and whole genome sequencing (WGS) on human samples for research projects, such as population sequencing initiatives, as well as offers sequencing and data analysis services to support population sequencing initiatives. Its customers include pharmaceutical companies, biopharmaceutical companies, diagnostics companies, universities, non-profits, government entities, and patients. The company was incorporated in 2011 and is headquartered in Fremont, California.GeneDx NASDAQ:WGS$40.70 +5.99 (+17.25%) As of 03:50 PM Eastern This is a fair market value price provided by Massive. Learn more.GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights. It provides genetic diagnostic tests, screening solutions, and information with a focus on pediatrics, rare diseases for children and adults, and hereditary cancer screening. GeneDx Holdings Corp. was founded in 2017 and is headquartered in Stamford, Connecticut. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Amprius Technologies Ups the Voltage on Forward Outlook Why Lam Research Still Looks Like a Buy After a 300% Rally Super Micro Surges Over 20% as Margins Soar, Sales Fall Short Nuts and Bolts AI Play Gains Momentum: Astera Labs Targets Raised Anheuser-Busch Stock Jumps as Volume Growth Signals Turnaround Light Speed Returns: Corning Cashes In on NVIDIA Growth Boarding Passes Now Being Issued for the Ultimate eVTOL Arbitrage DigitalOcean’s AI Surge: How Far Can This Rally Go? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
